THE BALANCEhttps://thebalance.clinic/resources/mental-health/personality/ceos-and-psychopathy/
THE BALANCE

Private admissions

Let’s talk about your next step.

Speak with our admissions team about treatment for you or someone you care about.

Your admissions team

Jil Moore
Jil MooreClient Relations Director
Cynthia Nakhle
Cynthia NakhleAdmissions Manager
Abdullah Boulad, Founder & CEO

Prefer to speak with our founder?

Abdullah Boulad · Founder & CEO

Clinical resource

CEOs and Psychopathy: What the Research Can Establish

A careful look at corporate psychopathy research, the limits of CEO prevalence claims, and practical responses to harmful workplace behavior.

Clinically reviewed byDr. Sarah Boss, MD
Stone residence with a swimming pool, lawn and palm trees

Quick Summary

  • A frequently cited study examined 203 selected corporate professionals.
  • Results from that sample do not establish prevalence among all CEOs.
  • Workplace concerns are better addressed through specific conduct and appropriate support.

Research on psychopathic traits in the workplace raises legitimate questions about leadership and organizational harm. It does not justify diagnosing a named executive from business decisions, a public persona or a newspaper account. Nor does a finding in a selected management sample establish the proportion of all CEOs who have a clinical condition.

What the frequently cited study actually studied

In a 2010 study by Paul Babiak, Craig Neumann and Robert Hare, the sample consisted of 203 corporate professionals selected by their companies for management development programs. This sampling detail matters. The participants were not a random sample of every CEO, business owner or worker.

Applying a percentage from that group to all CEOs requires evidence that the group represents that wider population. It also requires clarity about the assessment instrument, the threshold used and whether a result concerns a trait score or a clinical conclusion. Headline figures that omit these details can imply far more certainty than the study supports.

Traits, diagnosis and conduct are different questions

Psychopathy is a clinical and research construct, not a standalone DSM-5 diagnosis or a synonym for antisocial personality disorder. A research measure can explore relationships between personality characteristics and workplace outcomes. That is different from evaluating an individual patient. It is also different from establishing whether a specific decision was unethical, unlawful or harmful.

Calling a difficult leader a psychopath does not explain the evidence for a workplace complaint. Equally, avoiding a diagnostic label does not excuse bullying, intimidation, deception or retaliation. Those behaviors can be addressed on their own facts.

A more useful approach to workplace concerns

Describe what happened, when it happened and its effect. Separate direct observations from assumptions about motives. When safe and appropriate, retain relevant communications and use an established reporting route, such as a manager outside the reporting line or human resources. An employee assistance service or independent adviser may provide support, but is not necessarily a formal reporting route.

Consider the limits of each route. An employer’s investigation and a confidential clinical consultation serve different purposes. Before sharing sensitive information, ask who will receive it, how it will be used and what confidentiality exceptions apply. If there are threats or immediate danger, seek local emergency or safeguarding help.

Support for leaders and employees

Workplace distress, impulsive decisions or persistent relationship conflict may be reasons to seek professional support. The assessment should consider the individual’s difficulties and circumstances. It should not begin by assuming a diagnosis based on job title or wealth.

NICE guidance on antisocial personality disorder calls for a comprehensive assessment that includes functioning, co-occurring conditions and risk where relevant. It does not support a special diagnosis from an executive profile or a guarantee that luxury accommodation produces a better clinical outcome.

Editorial correction: This page replaces named-person speculation, generalized CEO prevalence claims and unsupported claims about a specialized treatment service that appeared in the earlier version.

What this includes
01

Clinical context

Clear information is framed around complex and co-occurring presentations.

02

Individual factors

Assessment remains essential because needs and risks differ from person to person.

03

Next steps

A confidential conversation can help clarify the most appropriate route forward.

Not sure where the situation fits?

Your admissions team

Jil Moore
Jil MooreClient Relations Director
Cynthia Nakhle
Cynthia NakhleAdmissions Manager

A confidential first conversation can help clarify the presentation and whether our setting is appropriate.

THE BALANCE
A PLACE TO BEGIN

Ask about our care